223 related articles for article (PubMed ID: 9033632)
1. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.
Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG
Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632
[TBL] [Abstract][Full Text] [Related]
2. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
3. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
4. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
5. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
6. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
7. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
8. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
10. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
[TBL] [Abstract][Full Text] [Related]
12. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
13. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line.
Bakker AB; Schreurs MW; Tafazzul G; de Boer AJ; Kawakami Y; Adema GJ; Figdor CG
Int J Cancer; 1995 Jul; 62(1):97-102. PubMed ID: 7541395
[TBL] [Abstract][Full Text] [Related]
15. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.
Lawendowski CA; Giurleo GM; Huang YY; Franklin GJ; Kaplan JM; Roberts BL; Nicolette CA
J Immunol; 2002 Sep; 169(5):2414-21. PubMed ID: 12193709
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
17. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
18. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]